This analysis demonstrates improved outcomes in diabetic retinopathy patients, suggesting Vessel Due F aids preoperative preparation.
Diabetic retinopathy (DR) remains one of the leading causes of reversible and irreversible blindness among the working-age population. According to a systematic review, the global prevalence of DR among patients with diabetes mellitus is 22.27% (95% CI: 19.73–25.03%), and the number of cases may increase from 103.12 million in 2020 to 160.5 million by 2045 [2]. Particularly high rates are observed in Africa (35.9%) and North America with the Caribbean (33.3%). The aim of this study was to evaluate the effectiveness of the drug Vessel Due F in the preoperative preparation of patients with preproliferative diabetic retinopathy (PPDR) before laser photocoagulation. The study included patients who received Vessel Due F according to three different administration regimens. The data obtained indicate a reduction in the number of laser coagulation sessions and an improvement in the overall condition of patients.
No takes yet. Share an insight, caveat, or question.
Umetaliev et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: